Abstract
Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.
| Original language | English |
|---|---|
| Journal | Annals of Oncology |
| Volume | 18 |
| Issue number | SUPPL. 6 |
| DOIs | |
| Publication status | Published - Jun 2007 |
Fingerprint
Keywords
- Breast cancer
- Cardiotoxicity
- Liposomal anthracyclines
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Role of liposomal anthracyclines in breast cancer. / Lorusso, V.; Manzione, L.; Silvestris, N.
In: Annals of Oncology, Vol. 18, No. SUPPL. 6, 06.2007.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of liposomal anthracyclines in breast cancer
AU - Lorusso, V.
AU - Manzione, L.
AU - Silvestris, N.
PY - 2007/6
Y1 - 2007/6
N2 - Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.
AB - Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.
KW - Breast cancer
KW - Cardiotoxicity
KW - Liposomal anthracyclines
UR - http://www.scopus.com/inward/record.url?scp=35748950745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748950745&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdm229
DO - 10.1093/annonc/mdm229
M3 - Article
C2 - 17591837
AN - SCOPUS:35748950745
VL - 18
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - SUPPL. 6
ER -